With Abbott as Its First RNAi Partner, Liquidia Remains on the Lookout for Additional Alliances | GenomeWeb

Having just forged its first alliance in the RNAi field with Abbott, Liquidia Technologies remains on the lookout for other companies interested in using its nanoparticle design and manufacturing platform to make drugs based on the gene-silencing technology, a company official told RNAi News last week.

However, Liquidia COO Luke Roush added that the company does not expect to begin any in-house RNAi programs in the foreseeable future.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.